Mission Therapeutics appoints Colin Goddard to board
This article was originally published in Scrip
Executive Summary
Mission Therapeutics, a drug discovery and development company, has named Dr Colin Goddard, former CEO of OSI Pharmaceuticals, to its board of directors. Dr Goddard joined OSI as a research scientist in 1989 and led the transformation of the technology platform services company into a profitable fully integrated biopharmaceutical organization, becoming CEO in 1998. OSI was acquired by Astellas Pharma in June 2010 for $4bn.
You may also be interested in...
2020 Vision For Biopharma
Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020. With insights from executives, investors and consultancies, as well as our own experts, In Vivo can paint a picture of biopharma wins and woes expected in the new year and new decade.
Accessing CAR-T Therapies
Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.
Taking Aim At Advanced Therapies
Dmitry Kuzmin, managing partner, and Owen Smith, investment director, talk to In Vivo about 4BIO’s approach to venture investing in the biopharma sector: successes, red flags and targets for its second fund.
Need a specific report? 1000+ reports available
Buy Reports